Last updated: August 25, 2026
Serevent, GSK's brand of salmeterol xinafoate inhalation powder, is a mature long-acting beta2-agonist with limited standalone commercial momentum. Its original molecule patents have expired, asthma use is constrained by the FDA's long-acting beta-agonist safety requirements, and prescribers increasingly favor inhaled corticosteroid/long-acting beta-agonist combinations or newer triple therapies. Serevent retains a niche in chronic obstructive pulmonary disease, but its financial contribution is small relative to GSK's Advair, Trelegy, and respiratory franchise revenues.
What is Serevent and how is it used?
Serevent Diskus contains salmeterol xinafoate, equivalent to 50 micrograms of salmeterol per inhalation. It is administered twice daily for maintenance treatment of asthma and COPD. It is not indicated for the relief of acute bronchospasm and is not an appropriate rescue treatment.
For asthma, Serevent must be used with an inhaled corticosteroid. The FDA label carries a boxed warning against LABA monotherapy because of increased asthma-related death risk observed in historical studies. The safety restriction materially reduces Serevent's attractiveness as a standalone asthma product (FDA, 2023a).
| Product attribute |
Serevent profile |
| Active ingredient |
Salmeterol xinafoate |
| Drug class |
Long-acting beta2-adrenergic agonist |
| Dosage form |
Dry-powder inhalation via Diskus |
| Standard strength |
50 mcg per inhalation |
| Dosing |
One inhalation twice daily |
| Main indications |
Asthma maintenance and COPD maintenance |
| Acute rescue use |
No |
| US sponsor |
GlaxoSmithKline |
| FDA approval |
1990s; NDA 020091 |
| Primary commercial issue |
Mature LABA displaced by combination and triple therapies |
When does Serevent lose exclusivity?
Serevent has already lost effective patent exclusivity. The principal salmeterol compound and formulation protections expired years ago, with the relevant US exclusivity period ending by the early 2010s. Serevent's current commercial protection does not depend on an active composition-of-matter patent.
The more important barrier is technical substitution. A competitor must develop an inhaled product with equivalent delivered performance, dose uniformity, device operation, and manufacturing controls. Dry-powder inhalers create greater regulatory and manufacturing complexity than conventional oral solid products.
What patents protect Serevent?
The original patent estate covered salmeterol, related chemical structures, pharmaceutical compositions, and inhaled delivery. Those patents are historical rather than current commercial barriers.
The principal protection categories were:
- Salmeterol compound and chemical derivative patents.
- Salmeterol xinafoate composition patents.
- Dry-powder inhalation and device-related patents.
- Manufacturing and particle-engineering claims.
- Regulatory exclusivity associated with the original NDA.
The current Orange Book position should be assessed against the specific edition and product presentation because listed patents can change through delisting, expiration, or product discontinuation. The commercial conclusion is stable: Serevent has no durable molecule-level patent moat, and any remaining patent value is likely to be narrow, device-specific, or expired. FDA Orange Book records should be used for a transaction or litigation opinion (FDA, 2024).
What is the FDA regulatory status of Serevent?
Serevent remains an FDA-approved prescription maintenance product. Its regulatory status is defined by the LABA safety framework.
The FDA requires that LABAs used for asthma be prescribed with an inhaled corticosteroid. The agency's review of combination therapy concluded that fixed-dose ICS/LABA products do not carry the same asthma-related risk profile as LABA monotherapy when used according to labeling. This regulatory distinction favors Advair, Breo Ellipta, Symbicort, Dulera, and generic fluticasone/salmeterol over Serevent as an asthma product (FDA, 2017).
Serevent has a stronger regulatory fit in COPD because the FDA's LABA monotherapy restriction is primarily an asthma safety issue. Even in COPD, however, long-acting muscarinic antagonists, ICS/LABA combinations, and triple inhalers compete directly for maintenance therapy.
How has Serevent revenue changed over time?
GSK does not consistently report Serevent as a separate revenue line in recent annual reports. It has historically reported Serevent within broader respiratory or established-product categories, while the company has emphasized larger products such as Advair, Seretide, Breo, Trelegy, and asthma biologics.
The revenue trajectory is therefore best described by product-cycle stages rather than a precise current sales series.
| Period |
Financial trajectory |
Main driver |
| 1990s to early 2000s |
Growth and broad adoption |
LABA expansion in asthma and COPD |
| Mid-2000s |
Mature high-value respiratory product |
Established Serevent and growing combination use |
| Late 2000s to mid-2010s |
Decline |
Advair substitution, patent expiry, safety restrictions |
| Late 2010s |
Low-growth mature brand |
Generic competition and portfolio rationalization |
| 2020s |
Niche, low strategic priority |
COPD demand, residual brand loyalty, limited pricing power |
Serevent's peak commercial period occurred before the full shift toward fixed-dose ICS/LABA therapy. Advair combined fluticasone and salmeterol in one inhaler and captured much of the value that otherwise would have been divided between separate inhaled corticosteroid and LABA products. The same active LABA therefore contributed more economic value through Advair than through standalone Serevent.
GSK's respiratory revenue is now concentrated in products with greater clinical differentiation or combination value. Trelegy Ellipta, which combines fluticasone furoate, umeclidinium, and vilanterol, is positioned for broader COPD and asthma use and has a stronger commercial profile than Serevent (GSK, 2024).
What is the current market size for salmeterol and Serevent?
The standalone salmeterol market is materially smaller than the broader LABA market. Most economic value has migrated to combination products, particularly:
- Fluticasone/salmeterol, including Advair and authorized or generic equivalents.
- Budesonide/formoterol, including Symbicort and generics.
- Fluticasone furoate/vilanterol, including Breo Ellipta.
- Triple inhalers such as Trelegy Ellipta and Breztri Aerosphere.
- Long-acting muscarinic antagonist products used alone or in combination.
Serevent competes against these products despite having a different delivery and ingredient profile. Its principal commercial disadvantages are:
- It does not provide inhaled corticosteroid therapy for asthma.
- It requires twice-daily dosing.
- Its Diskus device is mature and lacks significant product differentiation.
- Generic or lower-cost alternatives reduce brand leverage.
- Physicians increasingly use combination or triple therapy under guideline-based treatment pathways.
Serevent's remaining demand is concentrated among established COPD patients, patients who tolerate salmeterol well, and markets where the product remains reimbursed or clinically familiar.
Which companies are challenging Serevent?
The competitive threat comes from two groups: manufacturers of equivalent or near-equivalent salmeterol products and manufacturers of substitute respiratory therapies.
Generic and equivalent-product competitors
Generic competition is more difficult than for a tablet because the product requires device-specific equivalence. A competitor must demonstrate pharmaceutical equivalence and comparable inhalation performance, including dose delivery and aerodynamic particle characteristics.
The relevant competitive set includes:
- Generic salmeterol dry-powder inhalers, where approved and commercially available.
- Other inhaled LABAs, including formoterol and olodaterol.
- Generic fluticasone/salmeterol products, which compete for the same asthma and COPD patients.
- Budesonide/formoterol generics and branded alternatives.
The largest economic threat is not necessarily a direct Serevent generic. Generic Advair and other ICS/LABA alternatives can replace Serevent in asthma while providing a more complete treatment regimen.
Branded therapeutic competitors
| Product |
Sponsor or major manufacturer |
Competitive position |
| Advair and authorized/generic equivalents |
GSK; multiple generic manufacturers |
Directly leverages salmeterol in combination with fluticasone |
| Breo Ellipta |
GSK |
Once-daily ICS/LABA alternative |
| Symbicort |
AstraZeneca; generic manufacturers |
Major ICS/LABA competitor |
| Dulera |
Organon/Merck legacy product |
ICS/LABA alternative |
| Trelegy Ellipta |
GSK |
Triple therapy with strong COPD positioning |
| Anoro Ellipta |
GSK |
LAMA/LABA COPD competitor |
| Spiriva |
Boehringer Ingelheim |
Major LAMA competitor |
| Breztri Aerosphere |
AstraZeneca |
Triple therapy competitor |
What generic entry risks exist for Serevent?
Generic entry risk is high in principle and moderate in practical execution.
Legal risk
The original active-ingredient protection has expired. A new abbreviated new drug application would not face a live molecule patent barrier unless an unexpired product or device patent were listed and enforceable. Paragraph IV litigation risk is therefore limited compared with newer respiratory products.
A generic applicant could challenge any remaining listed patent by certifying that the patent is invalid, unenforceable, or not infringed. For a mature product such as Serevent, the commercial value of litigation may be constrained by low market size and the cost of developing a comparable inhaler.
Regulatory risk
FDA approval requires more than matching the nominal 50-microgram strength. Key issues include:
- Device design and operating characteristics.
- Delivered-dose uniformity.
- Particle-size distribution.
- Inhalation resistance.
- Dose-counter performance.
- Batch-to-batch manufacturing consistency.
- Human-factor and usability data where required.
- Demonstration of bioequivalence under the FDA's product-specific guidance.
These requirements can delay or prevent entry even after patent expiry. Inhaled products have historically generated fewer approved generics than oral products because the device, formulation, and manufacturing process are integrated.
Commercial risk
A direct Serevent generic would enter a declining segment with limited promotional support. Pharmacy substitution could reduce brand volume quickly, but low underlying demand can make launch economics unattractive. The more important pricing pressure comes from generic combination inhalers and payer preference for lower-cost maintenance therapy.
What formulation and manufacturing IP remains relevant?
The main defensible know-how is likely to reside in inhalation manufacturing rather than active-ingredient chemistry.
Relevant technical areas include:
- Micronized salmeterol particle production.
- Lactose carrier selection and blending.
- Powder-flow and deagglomeration properties.
- Device resistance and dose metering.
- Moisture control and stability.
- Filling and packaging processes.
- In-process testing for delivered dose and aerodynamic performance.
These elements can create practical barriers without producing a strong patent monopoly. Trade secrets, process validation, supplier control, and regulatory history may matter more than expired patent claims.
For licensing or acquisition analysis, a buyer should distinguish between patent protection, regulatory know-how, manufacturing capability, and brand goodwill. Serevent's patent position is weak, but an established inhaler supply chain can still reduce operating risk.
What patent litigation and Paragraph IV settlements affect Serevent?
Serevent is not currently associated with a major active Paragraph IV litigation wave comparable with newer inhaled products. Historical disputes centered on inhaler patents, combination products, and the broader Advair franchise rather than a durable standalone salmeterol monopoly.
The most commercially relevant settlement and litigation history involves generic challenges to fluticasone/salmeterol products. Those proceedings affected the timing of generic Advair entry and indirectly reduced demand for Serevent because the combination product is a more complete asthma treatment.
For current diligence, the practical legal conclusion is:
- No meaningful active compound-patent barrier protects Serevent.
- Direct litigation exposure is lower than for Advair, Trelegy, or newer inhaled therapies.
- Device and formulation claims remain the only plausible patent-based barriers.
- Any settlement value is limited by the size and trajectory of the standalone market.
How does Serevent compare with Advair and Trelegy?
| Factor |
Serevent |
Advair/generic fluticasone-salmeterol |
Trelegy Ellipta |
| Ingredients |
LABA |
ICS/LABA |
ICS/LAMA/LABA |
| Main strength |
Established LABA |
Complete combination therapy |
Broad maintenance and triple-therapy positioning |
| Asthma suitability |
Only with ICS |
Directly aligned with ICS/LABA treatment |
Approved for selected asthma patients |
| COPD suitability |
Yes |
Yes |
Strong positioning |
| Dosing frequency |
Twice daily |
Usually twice daily for Diskus; some presentations differ |
Once daily |
| Patent strength |
Expired or weak |
Mixed by product and jurisdiction |
Stronger residual estate |
| Generic pressure |
High |
High and established |
Lower than Serevent |
| Commercial trajectory |
Declining or stable niche |
Mature but materially larger |
Growth-oriented relative to Serevent |
| Strategic importance to GSK |
Low |
Historically high |
High |
Serevent's active ingredient is valuable in combination products but has limited standalone value. The commercial performance of salmeterol should not be confused with the performance of Serevent because Advair captures a much larger share of salmeterol-related economics.
What are the geographic market dynamics?
The United States has the clearest erosion risk because of generic substitution, formulary controls, and the availability of generic ICS/LABA products. Europe has similar clinical substitution pressures, although reimbursement, device preference, and national tender systems affect the speed of decline.
Emerging markets may retain branded Serevent demand longer because:
- Generic inhaler penetration is uneven.
- Physician familiarity can support legacy brands.
- Local device competition may be limited.
- COPD diagnosis and treatment are expanding.
Pricing in these markets is generally lower, and local manufacturing or regulatory requirements can reduce net contribution. Geographic diversification therefore supports volume more than margin.
What generic launch scenarios exist for Serevent?
Scenario 1: Direct generic launch
A salmeterol dry-powder equivalent reaches the market and obtains substitution status. Brand volume falls rapidly, while price erosion limits any residual branded revenue.
Scenario 2: Indirect substitution
No major standalone generic launches, but generic Advair, Symbicort, or other combination products replace Serevent. This is the most important ongoing risk because it follows treatment guidelines and payer economics.
Scenario 3: Managed niche stability
Serevent remains available for a limited COPD population and established patients. GSK maintains supply but reduces promotion. Revenue declines slowly as clinicians transition patients to newer products.
Scenario 4: Regional withdrawal
GSK withdraws the product from selected low-volume markets while maintaining availability in jurisdictions with persistent demand or contractual reimbursement.
How strong is the Serevent patent estate?
Serevent has a weak current patent estate and a stronger historical commercial record than current exclusivity profile.
| Patent-estate factor |
Assessment |
| Active composition-of-matter protection |
None of material commercial significance |
| Formulation protection |
Mostly expired or narrow |
| Device protection |
Potentially relevant but limited |
| Method-of-use protection |
Constrained by mature indications and prior art |
| Manufacturing protection |
More likely to operate as know-how and trade secret |
| Paragraph IV exposure |
Limited active risk |
| Generic substitution risk |
High |
| Residual brand value |
Moderate in selected COPD markets, low strategically |
Key Takeaways
- Serevent is a mature salmeterol product with no meaningful molecule-level exclusivity.
- Its standalone asthma role is restricted because LABA therapy must be combined with an inhaled corticosteroid.
- Generic Advair and other combination inhalers are more important competitive threats than a direct salmeterol generic.
- Dry-powder inhaler equivalence creates regulatory and manufacturing barriers, but those barriers do not restore patent exclusivity.
- GSK's respiratory value has shifted toward Trelegy, Breo, combination products, and biologic therapies.
- Serevent revenue is not generally disclosed as a separate material line item in recent GSK reporting.
- The most likely financial path is continued erosion, with limited residual demand in COPD and selected international markets.
- A direct Paragraph IV campaign would face a commercially small target unless bundled with a wider inhaler strategy.
FAQs
Is Serevent still available in the United States?
Serevent Diskus remains an FDA-approved product, although availability can vary by channel, wholesaler inventory, payer coverage, and regional commercial decisions.
Is salmeterol the same drug as Advair?
No. Salmeterol is the LABA component of Advair. Advair also contains fluticasone propionate, an inhaled corticosteroid.
Can Serevent be used alone for asthma?
No. FDA labeling requires asthma patients using Serevent to receive an inhaled corticosteroid and prohibits LABA monotherapy for asthma.
Does Serevent have biosimilar competition?
No. Serevent is a small-molecule inhaled drug, not a biologic. The relevant competition is generic or follow-on inhaler competition, not biosimilars.
Why are generic Serevent products less common than generic tablets?
Inhaled generics must match the formulation, device, emitted dose, particle-size distribution, airflow performance, and manufacturing controls. These requirements make development more complex and expensive than conventional oral products.
References
- AstraZeneca. (2024). Annual report and form 20-F 2023.
- GlaxoSmithKline plc. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2017). FDA drug safety communication: FDA review finds additional data support the safety of LABAs when used in combination with inhaled corticosteroids.
- U.S. Food and Drug Administration. (2023a). Serevent Diskus prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023b). Product-specific guidance for salmeterol xinafoate inhalation powder.
